New classifications and pathophysiology of the inflammatory myopathies

被引:17
作者
Benveniste, O. [1 ]
Dubourg, O. [1 ]
Herson, S. [1 ]
机构
[1] Assistance Publ Hop Paris, Fac Med Pitie Salpetriere, Grp Hop Pitie Salpetriere, Lab Neuropathol Serv Med Interne 1, F-75651 Paris, France
来源
REVUE DE MEDECINE INTERNE | 2007年 / 28卷 / 09期
关键词
dermatomyositis; polymyositis; inclusion body myositis; overlap myositis; auto-antibobies; pathogenesis;
D O I
10.1016/j.revmed.2007.03.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Scope. - Review on new classifications of myositis linked with their different pathophysiology. Current situation and salient points. - The classification of myositis refined recently, taking into account clinical (such as isolated muscle involvement or not, association with cancer...), immunological (presence or absence of auto-antibodies) and pathological criteria. This new classification has the ability to separate different clinical and physiopathological entities, having actually different prognosis factors. The most common inflammatory myopathies include dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), but also, overlap myositis (defined, among others, by the presence of auto-antibodies), and myositis associated to cancers. These myopathies may be also distinguished by their histological features which also reflect their different underlying pathogeneses. The mechanism of DM is complement-mediated microangiopathy, the inflammatory infiltrate being secondary to ischaemic damage. In PM the muscle fibres are damaged by cytotoxic CD8 T lymphocytes. IBM may be a degenerative disease with accumulation of a variety of proteins within the fibres. The inflammatory infiltrate, which is similar to that seen in PM, may be secondary to accumulated proteins. Perspectives. - These diseases with different pathogeny and prognosis should be treated by specific approaches. That is the reason why we initiated specific clinical trials for respectively inclusion body myositis and overlap myositis. (c) 2007 Elsevier Masson SAS. Tous droits reserves.
引用
收藏
页码:603 / 612
页数:10
相关论文
共 56 条
[11]   POLYMYOSITIS AND DERMATOMYOSITIS .1. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) :344-347
[12]   In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype [J].
Chinoy, H ;
Salway, F ;
Fertig, N ;
Shephard, N ;
Tait, BD ;
Thomson, W ;
Isenberg, DA ;
Oddis, CV ;
Silman, AJ ;
Ollier, WER ;
Cooper, RG .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (01)
[13]   Multiple sclerosis [J].
Compston, A ;
Coles, A .
LANCET, 2002, 359 (9313) :1221-1231
[14]   DERMATOMYOSITIS WITHOUT MUSCLE WEAKNESS - LONG-TERM FOLLOW-UP OF 12 PATIENTS WITHOUT SYSTEMIC CORTICOSTEROIDS [J].
COSNES, A ;
AMAUDRIC, F ;
GHERARDI, R ;
VERROUST, J ;
WECHSLER, J ;
REVUZ, J ;
ROUJEAU, JC .
ARCHIVES OF DERMATOLOGY, 1995, 131 (12) :1381-1385
[15]   POLYMYOSITIS, DERMATOMYOSITIS, AND INCLUSION-BODY MYOSITIS [J].
DALAKAS, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (21) :1487-1498
[16]   Differential expression of chemokines in inflammatory myopathies [J].
De Bleecker, JL ;
De Paepe, B ;
Vanwalleghem, IE ;
Schröder, JM .
NEUROLOGY, 2002, 58 (12) :1779-1785
[17]  
DEBLEECKER JL, 1995, AM J PATHOL, V146, P1178
[18]   Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis [J].
Dimitri, D ;
Benveniste, O ;
Dubourg, O ;
Maisonobe, T ;
Eymard, B ;
Amoura, Z ;
Jean, L ;
Tiev, K ;
Piette, JC ;
Klatzmann, D ;
Herson, S ;
Boyer, O .
BRAIN, 2006, 129 :986-995
[19]   Myopathy associated with anti-signal recognition peptide antibodies: Clinical heterogeneity contrasts with stereotyped histopathology [J].
Dimitri, Dalia ;
Andre, Chantal ;
Roucoules, Jacques ;
Hosseini, Hassan ;
Humbel, Rene-Louis ;
Authier, Francois-Jerome .
MUSCLE & NERVE, 2007, 35 (03) :389-395
[20]   MICROVASCULAR CHANGES IN EARLY AND ADVANCED DERMATOMYOSITIS - A QUANTITATIVE STUDY [J].
EMSLIESMITH, AM ;
ENGEL, AG .
ANNALS OF NEUROLOGY, 1990, 27 (04) :343-356